Sodium Benzoate

Summary

Sodium Benzoate (CHEMBL1356) is an approved small-molecule EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor (ATC A16AX11); indicated across 2 conditions including psychotic disorder and brain disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A16AX11
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 144.1 Da · C7H5NaO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1356
Name	Sodium Benzoate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	517055
ChEBI	CHEBI:113455
ATC	A16AX11
Molecular formula	C7H5NaO2
Molecular weight	144.1
InChIKey	WXMKPNITSTVMEF-UHFFFAOYSA-M

SMILES: C1=CC=C(C=C1)C(=O)[O-].[Na+]

IUPAC name: sodium benzoate

ChEBI definition: An organic sodium salt resulting from the replacement of the proton from the carboxy group of benzoic acid by a sodium ion.

Pharmacological roles (ChEBI): drug allergen, EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor, EC 3.1.1.3 (triacylglycerol lipase) inhibitor.

Other ChEBI roles (chemical / environmental): antimicrobial food preservative, algal metabolite, human xenobiotic metabolite, plant metabolite.

Also known as: Amzoate, Antimol, E-211, E211, FEMA NO. 3025, Fuminaru, INS NO.211, INS-211, Microcare sb, Mthwsh, Purox s, Sobenate

Patent coverage: 93,490 distinct patent families (244,527 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 4, Carbonic anhydrase.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	2	MONDO:0005485	EFO:0005407
brain disorder	2	MONDO:0005560	HP:0001298

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	4
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004767	PHASE2	COMPLETED	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders
NCT02026947	PHASE2	WITHDRAWN	Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.
NCT03510741	PHASE2	COMPLETED	Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
NCT06340789	PHASE2	UNKNOWN	Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
NCT02111200	Not specified	COMPLETED	Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
NCT04022941	Not specified	COMPLETED	Efficacy and Safety of Sodium Benzoate in the Management of Hyperammonemia in Infants, Children and Adolescent With Chronic Liver Disease.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).